DOSING REGIMEN OF THERAPEUTIC AGENT FOR ATAXIA ASSOCIATED WITH SPINOCEREBELLAR DEGENERATION

摘要

The present invention addresses the problem of providing a medicinal composition for treating ataxia associated with spinocerebellar degeneration, said medicinal composition reducing a risk of side effects caused by an increase in parathyroid hormone level and being excellent. Provided is a medicinal composition for treating ataxia associated with spinocerebellar degeneration, said medicinal composition being characterized by being to be dosed once a day and containing, as an active ingredient, rovatirelin in a daily dose of 1.6-3.2 mg or a pharmacologically acceptable salt of rovatirelin in a daily dose of 1.6-3.2 mg in terms of a free salt. The medicinal composition according to the present invention is highly useful as a therapeutic agent for ataxia associated with spinocerebellar degeneration.